Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.21 Insider Own11.07% Shs Outstand266.04M Perf Week0.00%
Market Cap1.13B Forward P/E- EPS next Y-0.65 Insider Trans0.00% Shs Float236.59M Perf Month8.97%
Income-221.26M PEG- EPS next Q-0.19 Inst Own54.89% Short Float2.88% Perf Quarter-11.46%
Sales10.50M P/S107.68 EPS this Y34.97% Inst Trans-1.84% Short Ratio3.89 Perf Half Y-32.75%
Book/sh1.64 P/B2.59 EPS next Y16.75% ROA-32.50% Short Interest6.81M Perf Year57.41%
Cash/sh2.85 P/C1.49 EPS next 5Y- ROE-52.13% 52W Range2.01 - 7.45 Perf YTD-34.01%
Dividend Est.- P/FCF- EPS past 5Y3.32% ROI-25.82% 52W High-42.95% Beta2.10
Dividend TTM- Quick Ratio18.25 Sales past 5Y152.23% Gross Margin38.34% 52W Low111.44% ATR (14)0.24
Dividend Ex-Date- Current Ratio18.25 EPS Y/Y TTM13.25% Oper. Margin-1666.66% RSI (14)56.79 Volatility4.57% 6.24%
Employees463 Debt/Eq0.48 Sales Y/Y TTM40.22% Profit Margin-2107.86% Recom1.20 Target Price10.10
Option/ShortYes / Yes LT Debt/Eq0.47 EPS Q/Q-3.58% Payout- Rel Volume0.00 Prev Close4.25
Sales Surprise-65.21% EPS Surprise-199.63% Sales Q/Q681.04% EarningsMay 17 BMO Avg Volume1.75M Price4.25
SMA2010.62% SMA506.12% SMA200-10.16% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-09-23Initiated Deutsche Bank Buy $10
Mar-27-23Resumed Wells Fargo Overweight $8
Mar-17-23Initiated Bryan Garnier Buy $5
Jun-14-21Upgrade Jefferies Hold → Buy $6 → $12
Jan-29-21Downgrade JP Morgan Overweight → Neutral $9
Dec-28-20Resumed H.C. Wainwright Buy $19
Jul-31-20Initiated JP Morgan Overweight
Jul-22-20Initiated SunTrust Buy $38
Apr-22-20Initiated Mizuho Buy $18
Sep-23-19Initiated Needham Buy $26
Jun-14-24 07:00AM
Jun-13-24 02:31PM
May-31-24 08:00AM
May-19-24 08:09AM
May-18-24 02:42AM
01:52PM Loading…
May-17-24 01:52PM
May-14-24 10:00AM
May-13-24 11:15AM
Apr-24-24 10:00AM
Apr-23-24 07:00AM
Apr-02-24 07:00AM
Apr-01-24 07:00AM
01:43AM Loading…
Mar-21-24 01:43AM
Mar-17-24 09:19AM
Mar-15-24 05:53AM
Mar-14-24 01:51PM
Mar-12-24 07:00AM
Mar-11-24 07:00AM
Mar-09-24 01:09PM
Feb-29-24 07:00AM
Feb-22-24 07:00AM
Feb-12-24 02:29AM
Feb-08-24 07:00AM
Jan-23-24 07:00AM
07:00AM Loading…
Jan-22-24 07:00AM
Jan-10-24 07:00AM
Dec-22-23 07:00AM
Dec-18-23 02:58PM
Dec-09-23 08:30PM
Nov-27-23 07:00AM
Nov-15-23 07:00AM
Nov-06-23 07:00AM
Nov-05-23 05:34PM
Nov-02-23 09:00AM
Oct-17-23 07:00AM
Oct-11-23 08:07AM
Sep-05-23 07:00AM
Aug-07-23 04:32PM
Aug-04-23 06:29AM
Aug-03-23 07:00AM
Jul-19-23 07:00AM
Jul-18-23 07:00AM
Jul-06-23 07:00AM
Jun-27-23 07:00AM
Jun-20-23 07:00AM
Jun-16-23 07:00AM
Jun-14-23 09:39AM
Jun-06-23 07:00AM
Jun-04-23 07:11AM
Jun-02-23 07:00AM
May-22-23 07:00AM
May-12-23 07:00AM
May-04-23 07:00AM
May-01-23 10:15AM
Apr-27-23 07:01AM
Apr-26-23 04:01PM
Apr-25-23 07:00AM
Apr-20-23 07:00AM
Apr-16-23 09:30AM
Apr-14-23 11:08AM
Apr-04-23 07:00AM
Mar-14-23 07:00AM
Mar-13-23 07:00AM
Mar-08-23 10:45PM
Mar-07-23 07:00AM
Feb-28-23 09:40AM
Feb-15-23 07:00AM
Feb-08-23 11:05AM
Jan-24-23 09:40AM
Jan-23-23 05:49AM
Jan-20-23 07:00AM
Jan-09-23 07:00AM
Dec-26-22 12:35PM
Dec-21-22 04:01PM
Dec-12-22 10:00AM
Dec-09-22 11:31AM
Dec-08-22 09:11PM
Nov-30-22 07:00AM
Nov-29-22 11:35AM
Nov-09-22 05:16AM
Nov-05-22 08:35AM
Nov-03-22 09:31AM
Oct-21-22 07:00AM
Oct-12-22 11:30AM
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.